2020
CLINICOPATHOLOGICAL IMPLICATIONS OF PRKAR1A MUTATION IN PATIENTS WITH CARDIAC MYXOMA: POOLED DATA ANALYSIS FROM 101 MYXOMA CASES
Altibi A, Al Jebbawi, Patel B, Vuong H, Masri A. CLINICOPATHOLOGICAL IMPLICATIONS OF PRKAR1A MUTATION IN PATIENTS WITH CARDIAC MYXOMA: POOLED DATA ANALYSIS FROM 101 MYXOMA CASES. Journal Of The American College Of Cardiology 2020, 75: 1195. DOI: 10.1016/s0735-1097(20)31822-2.Peer-Reviewed Original Research
2018
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
Vuong H, Ho A, Altibi A, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer 2018, 123: 76-82. PMID: 30089599, DOI: 10.1016/j.lungcan.2018.07.006.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMET exonCell lung cancerAdvanced non-small cell lung cancerLung cancerGenetic eventsOdds ratioPulmonary sarcomatoid carcinomaMeta-analysisConfidence intervalsC-Met inhibitorsRandom-effects modelSarcomatoid carcinomaPrognostic featuresClinicopathological profileDismal survivalTargeted therapyClinicopathological implicationsGenomic alterationsAdvanced ageWeb of ScienceC-MetNon-smokersRare mutationsPatients
2017
Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis
Vuong H, Altibi A, Duong U, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis. Clinical Endocrinology 2017, 87: 411-417. PMID: 28666074, DOI: 10.1111/cen.13413.Peer-Reviewed Original ResearchConceptsTERT promoter mutationsPapillary thyroid carcinomaPromoter mutationsRisk stratificationRisk stratification of papillary thyroid carcinomaAssociated with increased tumor aggressivenessManagement of papillary thyroid carcinomaGroup of papillary thyroid carcinomasPapillary thyroid carcinoma patientsPooled estimates of odds ratiosCombination of BRAFEstimates of odds ratiosRandom-effects modelCoexisting BRAFThyroid carcinomaPrognostic implicationsTumor aggressivenessClinicopathological implicationsBRAFClinical managementConcurrent BRAFRisk groupsOdds ratioVirtual Health LibraryWeb of Science